Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Non-Current Deferred Tax Liability (2016 - 2025)

Historic Non-Current Deferred Tax Liability for Standard Biotools (LAB) over the last 12 years, with Q3 2025 value amounting to $1.1 million.

  • Standard Biotools' Non-Current Deferred Tax Liability rose 3543.4% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 3543.4%. This contributed to the annual value of $1.1 million for FY2024, which is 2853.75% up from last year.
  • According to the latest figures from Q3 2025, Standard Biotools' Non-Current Deferred Tax Liability is $1.1 million, which was up 3543.4% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, Standard Biotools' Non-Current Deferred Tax Liability ranged from a high of $16.9 million in Q4 2021 and a low of $620000.0 during Q3 2022
  • Moreover, its 5-year median value for Non-Current Deferred Tax Liability was $1.1 million (2022), whereas its average is $2.9 million.
  • Its Non-Current Deferred Tax Liability has fluctuated over the past 5 years, first tumbled by 9374.81% in 2022, then skyrocketed by 6403.23% in 2023.
  • Quarter analysis of 5 years shows Standard Biotools' Non-Current Deferred Tax Liability stood at $16.9 million in 2021, then tumbled by 93.75% to $1.1 million in 2022, then dropped by 20.28% to $841000.0 in 2023, then grew by 28.54% to $1.1 million in 2024, then grew by 5.37% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q3 2025, $1.1 million for Q2 2025, and $1.0 million during Q1 2025.